Provided is an isolated anti-L-SIGN antibody, or an antigen-binding fragment thereof, that (a) does not bind to DC-SIGN or (b) selectively binds to L-SIGN as compared to DC-SIGN, wherein the anti-L-SIGN antibody is: (i) fully human, (ii) humanized, or (iii) chimeric, wherein the chimeric antibody comprises a non-human antibody variable domain and a human constant region and wherein the antibody or antigen-binding fragment thereof comprises specified combinations of heavy and light chain CDR1, CDR2 and CDR3 sequences. The antibodies can be used to treat autoimmune diseases.